Literature DB >> 23358607

Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.

M L O Shea1, L D Garfield, S Teitelbaum, R Civitelli, B H Mulsant, C F Reynolds, D Dixon, P Doré, E J Lenze.   

Abstract

UNLABELLED: Antidepressants are associated with bone loss and fractures in older adults. We treated depressed older adults with an antidepressant and examined its effects on bone turnover by comparing blood samples before and after treatment. Bone resorption increased after antidepressant treatment, which may increase fracture risk.
INTRODUCTION: Antidepressants have been associated with increased bone loss and fractures in older adults in observational studies, but the mechanism is unclear. We examined the effects of a serotonin-norepinephrine reuptake inhibitor, venlafaxine, on biomarkers of bone turnover in a prospective treatment study of late-life depression.
METHODS: Seventy-six individuals aged 60 years and older with current major depressive disorder received a 12-week course of venlafaxine XR 150-300 mg daily. We measured serum C-terminal cross-linking telopeptide of type I collagen (β-CTX) and N-terminal propeptide of type I procollagen (P1NP), measures of bone resorption and formation, respectively, before and after treatment. We then analyzed the change in β-CTX and P1NP within each participant. Venlafaxine levels were measured at the end of the study. We assessed depression severity at baseline and remission status after treatment.
RESULTS: After 12 weeks of venlafaxine, β-CTX increased significantly, whereas P1NP did not significantly change. The increase in β-CTX was significant only in participants whose depression did not remit (increase by 10 % in non-remitters vs. 4 % in remitters). Change in β-CTX was not correlated with serum levels of venlafaxine or norvenlafaxine.
CONCLUSION: Our findings suggest that the primary effect of serotonergic antidepressants is to increase bone resorption. However, such an increase in bone resorption seemed to depend on whether or not participants' depression remitted. Our results are in agreement with prior observational studies reporting increased bone loss in older adults taking serotonergic antidepressants. These negative effects on bone homeostasis could potentially contribute to increased fracture risk in older adults.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23358607      PMCID: PMC4066460          DOI: 10.1007/s00198-012-2170-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  51 in total

1.  Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth.

Authors:  Stuart J Warden; Alexander G Robling; Megan S Sanders; Michael M Bliziotes; Charles H Turner
Journal:  Endocrinology       Date:  2004-11-11       Impact factor: 4.736

2.  Depression and bone mineral density in a community sample of perimenopausal women: Geelong Osteoporosis Study.

Authors:  Felice N Jacka; Julie A Pasco; Margaret J Henry; Mark A Kotowicz; Seetal Dodd; Geoff C Nicholson; Michael Berk
Journal:  Menopause       Date:  2005 Jan-Feb       Impact factor: 2.953

3.  Bone mineral density and depression: a community study in women.

Authors:  R Coelho; C Silva; A Maia; J Prata; H Barros
Journal:  J Psychosom Res       Date:  1999-01       Impact factor: 3.006

4.  Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.

Authors:  Ellen M Whyte; James Basinski; Panthea Farhi; Mary Amanda Dew; Amy Begley; Benoit H Mulsant; Charles F Reynolds
Journal:  J Clin Psychiatry       Date:  2004-12       Impact factor: 4.384

5.  Depression induces bone loss through stimulation of the sympathetic nervous system.

Authors:  Raz Yirmiya; Inbal Goshen; Alon Bajayo; Tirzah Kreisel; Sharon Feldman; Joseph Tam; Victoria Trembovler; Valér Csernus; Esther Shohami; Itai Bab
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-30       Impact factor: 11.205

Review 6.  Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies.

Authors:  S J Warden; E M Haney
Journal:  J Musculoskelet Neuronal Interact       Date:  2008 Apr-Jun       Impact factor: 2.041

7.  Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men.

Authors:  Elizabeth M Haney; Benjamin K S Chan; Susan J Diem; Kristine E Ensrud; Jane A Cauley; Elizabeth Barrett-Connor; Eric Orwoll; M Michael Bliziotes
Journal:  Arch Intern Med       Date:  2007-06-25

8.  National patterns in antidepressant medication treatment.

Authors:  Mark Olfson; Steven C Marcus
Journal:  Arch Gen Psychiatry       Date:  2009-08

9.  A detailed examination of cytokine abnormalities in Major Depressive Disorder.

Authors:  N M Simon; K McNamara; C W Chow; R S Maser; G I Papakostas; M H Pollack; A A Nierenberg; M Fava; K K Wong
Journal:  Eur Neuropsychopharmacol       Date:  2007-08-03       Impact factor: 4.600

Review 10.  Bone turnover markers: understanding their value in clinical trials and clinical practice.

Authors:  R Civitelli; R Armamento-Villareal; N Napoli
Journal:  Osteoporos Int       Date:  2009-02-04       Impact factor: 4.507

View more
  18 in total

1.  Treatment Emergent Suicidal Ideation in depressed older adults.

Authors:  Pilar Cristancho; Brendan O'Connor; Eric J Lenze; Daniel M Blumberger; Charles F Reynolds; David Dixon; Benoit H Mulsant
Journal:  Int J Geriatr Psychiatry       Date:  2016-05-09       Impact factor: 3.485

Review 2.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

3.  Effects of drugs on bone metabolism in a cohort of individuals with traumatic spinal cord injury.

Authors:  Christina Kokorelis; Marlis Gonzalez-Fernandez; Marjorie Morgan; Cristina Sadowsky
Journal:  Spinal Cord Ser Cases       Date:  2019-01-16

Review 4.  Major depressive disorder in older adults: benefits and hazards of prolonged treatment.

Authors:  Breno S Diniz; Charles F Reynolds
Journal:  Drugs Aging       Date:  2014-09       Impact factor: 3.923

5.  Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study.

Authors:  C-Y Wang; S-H Fu; C-L Wang; P-J Chen; F-L L Wu; F-Y Hsiao
Journal:  Osteoporos Int       Date:  2015-07-01       Impact factor: 4.507

6.  Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults.

Authors:  Lauren D Garfield; Daniel J Müller; James L Kennedy; Benoit H Mulsant; Charles F Reynolds; Steven L Teitelbaum; Roberto Civitelli; David Dixon; Alexandre A Todorov; Eric J Lenze
Journal:  World J Biol Psychiatry       Date:  2013-09-30       Impact factor: 4.132

7.  Bone Turnover with Venlafaxine Treatment in Older Adults with Depression.

Authors:  Kerri S Rawson; David Dixon; Roberto Civitelli; Tim R Peterson; Benoit H Mulsant; Charles F Reynolds; Eric J Lenze
Journal:  J Am Geriatr Soc       Date:  2017-05-26       Impact factor: 5.562

Review 8.  Depression, antidepressants, and bone health in older adults: a systematic review.

Authors:  Marie Anne Gebara; Marcie L O Shea; Kim L Lipsey; Steven L Teitelbaum; Roberto Civitelli; Daniel J Müller; Charles F Reynolds; Benoit H Mulsant; Eric J Lenze
Journal:  J Am Geriatr Soc       Date:  2014-07-15       Impact factor: 5.562

9.  Serotonin regulates calcium homeostasis in lactation by epigenetic activation of hedgehog signaling.

Authors:  Jimena Laporta; Kimberly P Keil; Samantha R Weaver; Callyssa M Cronick; Austin P Prichard; Thomas D Crenshaw; Galen W Heyne; Chad M Vezina; Robert J Lipinski; Laura L Hernandez
Journal:  Mol Endocrinol       Date:  2014-09-05

10.  The effect of selective serotonin reuptake inhibitors on the human mandible.

Authors:  Aykağan Coşgunarslan; Firdevs Aşantoğrol; Damla Soydan Çabuk; Emin Murat Canger
Journal:  Oral Radiol       Date:  2020-01-02       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.